Growth Metrics

Eli Lilly (LLY) Non-Current Debt (2016 - 2026)

Eli Lilly filings provide 18 years of Non-Current Debt readings, the most recent being $39.4 billion for Q1 2026.

  • On a quarterly basis, Non-Current Debt rose 14.12% to $39.4 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $39.4 billion, a 14.12% increase, with the full-year FY2025 number at $40.9 billion, up 43.26% from a year prior.
  • Non-Current Debt hit $39.4 billion in Q1 2026 for Eli Lilly, down from $40.9 billion in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $40.9 billion in Q3 2025 to a low of $14.1 billion in Q3 2022.
  • Median Non-Current Debt over the past 5 years was $23.7 billion (2024), compared with a mean of $25.2 billion.
  • Biggest five-year swings in Non-Current Debt: dropped 8.88% in 2022 and later soared 62.05% in 2024.
  • Eli Lilly's Non-Current Debt stood at $14.7 billion in 2022, then rose by 24.31% to $18.3 billion in 2023, then skyrocketed by 55.71% to $28.5 billion in 2024, then soared by 43.26% to $40.9 billion in 2025, then dropped by 3.67% to $39.4 billion in 2026.
  • The last three reported values for Non-Current Debt were $39.4 billion (Q1 2026), $40.9 billion (Q4 2025), and $40.9 billion (Q3 2025) per Business Quant data.